Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities researchers at Gabelli increased their FY2020 earnings per share estimates for shares of Collegium Pharmaceutical in a note issued to investors on Thursday. Gabelli analyst K. Kedra now expects that the specialty pharmaceutical company will post earnings of $0.50 per share for the year, up from their previous forecast of $0.45. Gabelli also issued estimates for Collegium Pharmaceutical’s FY2021 earnings at $1.70 EPS.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.09. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $4.07 million. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%.
COLL has been the subject of several other reports. Piper Jaffray Companies set a $14.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, July 25th. Needham & Company LLC reissued a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, May 31st. ValuEngine raised Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Zacks Investment Research lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Finally, BidaskClub lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Three investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. Collegium Pharmaceutical currently has a consensus rating of “Hold” and a consensus target price of $21.33.
Collegium Pharmaceutical (NASDAQ:COLL) traded up 3.19% during mid-day trading on Friday, reaching $10.34. The company had a trading volume of 460,789 shares. Collegium Pharmaceutical has a 1-year low of $7.37 and a 1-year high of $20.55. The firm has a 50-day moving average of $12.14 and a 200 day moving average of $11.95. The company’s market capitalization is $305.71 million.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Macquarie Group Ltd. acquired a new position in shares of Collegium Pharmaceutical during the fourth quarter valued at $127,000. American International Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after buying an additional 2,163 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 1,422 shares in the last quarter. Credit Suisse AG boosted its stake in shares of Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares in the last quarter. Finally, UBS Group AG boosted its stake in shares of Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 10,174 shares in the last quarter. Hedge funds and other institutional investors own 82.27% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.